Blog
RSS FeedPosted by Michael Wonder on 12 Jan 2016
Dabrafenib in combination with trametinib in advanced melanoma with BRAF V600 mutation: indication of added benefit says IQWiG
4 January 2016 - According to the findings, no added benefit is proven for trametinib monotherapy because of a lack of ...
Posted by Michael Wonder on 05 Jan 2016
IQWIG Autumn Symposium 2015: presentations now online
5 January 2016 - Real world data: a gain for benefit assessments? This question was the focus of the Autumn Symposium ...
Posted by Michael Wonder on 22 Dec 2015
Evolocumab: no hint of added clinical benefit according the IQWiG in Germany
15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...
Posted by Michael Wonder on 15 Dec 2015
Evolocumab: no evidence of additional clinical benefits says IQWiG
15 December 2015 - The dossier did not contain appropriate data for patients with hypercholesterolaemia nor for mixed dyslipidaemia. ...
Posted by Michael Wonder on 04 Dec 2015
Neo-adjuvant use of pertuzumab in HER2-positive breast cancer: hint of lesser benefit
1 December 2015 - In a further dossier assessment, the IQWiG has examined the benefit of pertuzumab in its second therapeutic ...
Posted by Michael Wonder on 04 Dec 2015
Secukinumab in psoriasis: now an indication of an additional clinical benefit for certain patients
30 November 2015 - The extent of the additional clinical benefit varies by the type of prior therapy, however: It is ...
Posted by Michael Wonder on 25 Nov 2015
Netupitant with palonosetron hydrochloride for the prevention of nausea and vomiting: added benefit not proven says IQWiG
16 November 2015 - According to the findings, an added clinical benefit is not proven in moderately emetogenic or in highly ...
Posted by Michael Wonder on 23 Nov 2015
Pembrolizumab in advanced melanoma: additional clinical benefit for certain patients says German IQWiG
16 November 2015 - According to the findings, an additional clinical benefit can be derived for different patient groups: in pretreated ...
Posted by Michael Wonder on 19 Nov 2015
Tiotropium/olodaterol in COPD: IQWiG finds disadvantages in patients with more severe disease, advantages for some women
16 November 2015 - According to the findings, there were no statistically significant differences between the treatment groups for the totality ...
Posted by Michael Wonder on 18 Nov 2015
Insulin degludec plus liraglutide: again no hint of added benefit in type 2 diabetes says IQWiG
16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus ...
Posted by Michael Wonder on 18 Nov 2015
Nivolumab in non-small cell lung cancer: indication of major added benefit for under-75-year-olds
16 November 2015 - According to the findings, there is an indication of major added benefit of nivolumab over the appropriate ...
Posted by Michael Wonder on 16 Nov 2015
Nivolumab in non small-cell lung cancer: evidence of a considerable additional benefit in patients under 75 years of age according to IQWiG
16 November 2015 - For patients under 75 year of age with a relatively good general condition, there is an ...
Posted by Michael Wonder on 16 Nov 2015
Pembrolizumab has an additional benefit in certain patients with advanced melanoma says IQWiG
16 November 2015 - In treatment experienced patients in whom the use of ipilimumab as the next treatment is suitable, there is ...
Posted by Michael Wonder on 05 Nov 2015
Edoxaban tosylate: considerable additional benefit for certain patients
2 November 2015 - IQWiG finds an indication of a considerable additional benefit in comparison with vitamin K antagonists for the ...
Posted by Michael Wonder on 02 Nov 2015
Edoxaban tosylate has considerable additional benefits for certain patients says IQWiG
2 November 2015 - Edoxaban tosylate (Lixiana) has considerable additional benefit when compared to vitamin K antagonists for the prevention of ...